Multi-drug delivery system and uses thereof

Patent metadata

Field	Value
Publication number	US-10912832-B2
Application number	US-201916697810-A
Country	US
Kind code	B2
Filing date	Nov 27, 2019
Priority date	Jul 10, 2014
Publication date	Feb 9, 2021
Grant date	Feb 9, 2021

Abstract

Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemia disease is also provided.

First claim

What is claimed is:

1. A method of administering a PEGylated therapeutic to a subject in need thereof, comprising:
administering to the subject, a sufficient amount of, a mixture of an anti-PEG antibody and a hydrogel, before, together with or after administering the PEGylated therapeutic;
wherein,
the hydrogel is hyaluronan (HA);
the anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 to 1:100 (v/v); and
at least two applications of the PEGylated therapeutic are administered to the subject, with each applications being about 1 hour to 1 week apart.

2. The method of claim 1 , wherein the PEGylated therapeutic administered at each applications is different.

3. The method of claim 1 , wherein the PEGylated therapeutic administered at each applications is the same.

4. The method of claim 1 , wherein the PEGylated therapeutic and the mixture are administered to different sites of the subject.

5. The method of claim 1 , wherein the PEGylated therapeutic and the mixture are administered to the subject via different routes.

6. The method of claim 1 , wherein at least three applications of the PEGylated therapeutic are administered to the subject, with each applications being about 8 to 24 hours apart.

7. The method of claim 1 , wherein the anti-PEG antibody is an IgM, IgG, humanized IgM or humanized IgG; and the HA has a molecular weight of about 20 kDa to 2,000 kDa.

8. The method of claim 7 , wherein the HA has a molecular weight of about 1,500 kDa.

9. The method of claim 7 , wherein the anti-PEG antibody and the HA are present n the mixture in a ratio of about 1:4 (v/v).

10. The method of claim 1 , wherein the PEGylated therapeutic is suitable for treating cancer or ischemic disease.

11. The method of claim 10 , wherein the ischemic disease is stroke, myocardial infarction (MI) or limb ischemia.

12. The method of claim 11 , wherein the limb ischemia is any of critical limb ischemia, acute limb ischemia or Buerger's Disease.

13. The method of claim 10 , wherein the cancer is any of breast cancer, cervical cancer, ovary cancer, endometrial cancer, melanoma, uveal melanoma, brain tumor, lung cancer, liver cancer, lymphoma, neuroepithelioma, kidney cancer, bladder cancer, pancreatic cancer, prostate cancer, stomach cancer, colon cancer, uterus cancer, hematopoietic tumors of lymphoid lineage, myeloid leukemia, thyroid cancer, thyroid follicular cancer, myelodysplastic syndrome (MDS), tumor of mesenchymal origin, teratcarcinoma, neuroblastoma, glioma, glioblastoma, keratoacanthomas, analplastic large cell lymphoma, esophageal squamous cell carcinoma, follicular dentritic cell carcinoma, intestinal cancer, muscle invasive cancer, seminal vesicle tumor, epidermal carcinoma, spleen cancer, head and neck cancer, stomach cancer, bone cancer, cancer of retina, biliary cancer, small bowel cancer, salivary gland cancer, uterine sarcoma, cancer of testicles, cancer of connective tissue, prostatic hypertrophy, myelodysplasia, Waldenstrom's macroglobulinemia, nasopharyngeal, neuroendocrine cancer, mesothelioma, angiosarcoma, Kaposi's sarcoma, oesophagogastric, fallopian tube cancer, peritoneal cancer, papillary serous mullerian cancer, malignant ascites, gastrointestinal stromal tumor (GIST), Li-Fraumeni syndrome or Von Hippel-Lindau syndrome (VHL).

14. The method of claim 13 , wherein the hematopoietic tumors of lymphoid lineage may be any of leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, B-cell lymphoma, Burkitt's lymphoma, multiple myeloma, Hodgkin's lymphoma, or Non-Hodgkin's lymphoma.

Assignees

• Academia Sinica

Inventors

• Hsieh Patrick C H
• Wu Pei-Jung
• Roffler Steve
• Cheng Bill

Classifications

• A61K47/36

  Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin · CPC title

• A61K47/42

  Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34) · CPC title

• C07K16/44

  against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids} · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61K39/39583 Primary

  against materials not provided for elsewhere, e.g. haptens, coenzymes · CPC title